United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · IEX Real-Time Price · USD
262.40
+4.27 (1.65%)
At close: May 3, 2024, 4:00 PM
264.49
+2.09 (0.80%)
After-hours: May 3, 2024, 6:33 PM EDT
United Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for United Therapeutics stock have an average target of 308.78, with a low estimate of 240 and a high estimate of 400. The average target predicts an increase of 17.68% from the current stock price of 262.40.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for UTHR stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Buy | 5 | 5 | 4 | 5 | 5 | 6 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 9 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $218 → $240 | Hold | Maintains | $218 → $240 | -8.54% | May 3, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $375 → $400 | Buy | Maintains | $375 → $400 | +52.44% | May 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $300 | Strong Buy | Reiterates | $300 | +14.33% | May 2, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $309 → $325 | Buy | Maintains | $309 → $325 | +23.86% | Mar 7, 2024 |
| Wedbush | Wedbush | Buy Reiterates $308 | Buy | Reiterates | $308 | +17.38% | Feb 22, 2024 |
Financial Forecast
Revenue This Year
2.75B
from 2.33B
Increased by 18.32%
Revenue Next Year
2.88B
from 2.75B
Increased by 4.72%
EPS This Year
24.52
from 19.81
Increased by 23.77%
EPS Next Year
25.36
from 24.52
Increased by 3.43%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.8B | 3.3B | 3.8B | 4.5B | 5.2B |
| Avg | 2.8B | 2.9B | 3.2B | 3.4B | 3.6B |
| Low | 2.4B | 2.4B | 2.6B | 2.8B | 2.9B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 62.6% | 19.6% | 32.2% | 41.7% | 50.7% |
| Avg | 18.3% | 4.7% | 9.7% | 8.6% | 3.6% |
| Low | 3.8% | -11.9% | -9.0% | -12.9% | -16.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 33.35 | 30.18 | 32.98 | 28.21 | 25.60 |
| Avg | 24.52 | 25.36 | 26.69 | 27.13 | 24.87 |
| Low | 20.29 | 19.55 | 16.88 | 25.79 | 23.89 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 68.3% | 23.1% | 30.0% | 5.7% | -5.6% |
| Avg | 23.8% | 3.4% | 5.3% | 1.6% | -8.3% |
| Low | 2.4% | -20.3% | -33.5% | -3.4% | -11.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.